TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35866767
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with low-dose naloxone admixture at 0.2 μg·kg‐1·h‐1 (Group B)
Study: 35866767
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with naloxone admixture at 0.4 μg·kg‐1·h‐1 (Group C)
Study: 35866767
Drug: PCIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCIA with naloxone admixture at 0.6 μg·kg‐1·h‐1 (Group D)
Study: 34407811
Drug: INT-DPM (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: INT-DPM (with oral hypoglycaemic medication)
Study: 35195738
Drug: Single carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single carbon dioxide (CO2) laser maintenance treatment
Study: 35195738
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment control group
Study: 36495185
Drug: N-acetylcysteine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine inhalation spray (one puff per 12 hours for 7 days)
Study: 33588060
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (PDT + isotretinoin 10 mg twice a day for 3 months)
Study: 33882052
Drug: Daily cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cigarette smoking
Study: 32502705
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane block with dexmedetomidine (1 μg/kg)
Study: 32502705
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient‐controlled analgesia (Control group)
Study: 33843133
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by pelvic re-irradiation
Study: 33183258
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological saline solution)
Study: 33259482
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (2 μg daily for 12 months)
Study: 34865016
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg/day for 12 weeks
Study: 33285652
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (RT) for 30 minutes twice a day for 2 weeks
Study: 33285652
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation (CR) for 30 minutes twice a day for 2 weeks
Study: 35385097
Drug: 8 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 sessions of cognitive behavioral therapy
Study: 34323164
Drug: Selinexor 60
Normalized name: selinexor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 60 mg twice weekly
Study: 34323164
Drug: Physician’s choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician’s choice (PC) treatment
Study: 32598447
Drug: Prophylactic fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic fat injections (3 injections according to Coleman's technique) after radiotherapy and before expander removal with definitive implant insertion.
Study: 32222782
Drug: Metaphor-based visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaphor-based visual representations of pharmaceutical pollution risks
Study: 32222782
Drug: Non-metaphor visual
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-metaphor visual representations of pharmaceutical pollution risks
Study: 35106315
Drug: MHAA4549A (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHAA4549A (3600 mg or 8400 mg)
Study: 35246827
Drug: fosnetupitant 235
Normalized name: fosnetupitant 235 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosnetupitant 235 mg
Study: 34076981
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate combined with rituximab (HD-MTX + R)
Study: 34076981
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate combined with whole brain radiotherapy (WBRT)
Study: 35109906
Drug: Topical hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrogen peroxide
Study: 33271112
Drug: Perioperative endocrine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative endocrine therapy
Study: 99050129
Drug: Cocaine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (80 mg/70 kg, p.o.)
Study: 99050129
Drug: d-amphetamine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (5, 10, 20 mg/70 kg, p.o.)
Study: 99050129
Drug: Caffeine (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150, 300, 600 mg/70 kg, p.o.)
Study: 32827162
Drug: Eflapegrastim (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflapegrastim (fixed dose of 13.2 mg, 3.6 mg G-CSF)
Study: 32687266
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg G-CSF)
Study: 33946029
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (80 mg daily for 8 weeks)
Study: 34247409
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing regimen (higher dose)
Study: 34247409
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (control)
Study: 32522771
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by surgery (Arm A): three cycles of paclitaxel and cisplatin followed by type C radical hysterectomy and pelvic ± paraaortic lymphadenectomy.
Study: 32522771
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (Arm B): definitive concurrent chemoradiotherapy including external beam pelvic radiotherapy combined with concurrent weekly cisplatin followed by brachytherapy.
Study: 35546450
Drug: Once-weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly semaglutide (n=874)
Study: 35546450
Drug: Thrice-daily insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrice-daily insulin aspart (IAsp) (n=874)
Study: 36542260
Drug: Once-weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly semaglutide
Study: 35546450
Drug: Thrice-daily insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrice-daily insulin aspart (IAsp)
Study: 33044411
Drug: Specific intervention
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific intervention (plasma transfusion, low‐dose unfractionated heparin, and tranexamic acid)
Study: 33896590
Drug: Induced normothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced normothermia (maintaining core temperature at 37°C using external cooling, cold i.v. fluids, and medications like buspirone, clonidine, and magnesium sulphate)
Study: 36178169
Drug: High-dose green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose green tea extract (843 mg/day EGCG)
Study: 34183565
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 1 mg tablets
Study: 34183565
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol plus micronized progesterone (MP)
Study: 35567872
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa oil 1000 mg/day for 8 weeks
Study: 32121339
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g dark chocolate bar
Study: 32121339
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g white chocolate bar
Study: 32465723
Drug: Post-implant survival
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-implant survival
Study: 33507691
Drug: Curcumin +
Normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin + radiation therapy
Study: 33507691
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + radiation therapy
Study: 34340708
Drug: 3200 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3200 IU/day oral vitamin D3 for 12 weeks
Study: 34162485
Drug: Low-dose direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose direct acting oral anticoagulants (LDDOAC)
Study: 35064063
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug misuse campaign (control)
Study: 32471854
Drug: Fast-acting treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting treatment (BeSt and IMPROVED)
Study: 32471854
Drug: Slow-acting treatment
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-acting treatment (BeSt)
Study: 32471854
Drug: Slow-acting monotherapy
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-acting monotherapy
Study: 32471854
Drug: Fast-acting treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting treatment (BeSt)
Study: 32471854
Drug: Fast-acting treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting treatment (IMPROVED)
Study: 34765938
Drug: Early access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early access to antiretroviral therapy (ART)
Study: 34765938
Drug: Late access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Late access to antiretroviral therapy (ART)
Study: 36075590
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with intradermal needling
Study: 32897010
Drug: Antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy (ABT) + recombinant interferon alpha‐2b with antioxidant complex (vitamins E and C)
Study: 32897010
Drug: Antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy (ABT)
Study: 35270910
Drug: Active coil
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active coil stimulation for tests and placebo coil stimulation for treatment (APA) (n = 15)
Study: 32299820
Drug: Low-dose carfilzomib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carfilzomib (27 mg/m2) with dexamethasone
Study: 32299820
Drug: High-dose carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carfilzomib (56 mg/m2) with dexamethasone
Study: 32299820
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to high-dose carfilzomib (56 mg/m2) after progression on low-dose
Study: 32299820
Drug: High-dose carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carfilzomib (56 mg/m2)
Study: 32299820
Drug: Low-dose carfilzomib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carfilzomib (27 mg/m2)
Study: 32265061
Drug: DJT1116PG 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DJT1116PG 20 mg once daily for 7 days
Study: 32265061
Drug: DJT1116PG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DJT1116PG 50 mg once daily for 7 days
Study: 32265061
Drug: DJT1116PG 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DJT1116PG 100 mg once daily for 7 days
Study: 32265061
Drug: DJT1116PG (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DJT1116PG (all doses)
Study: 33495576
Drug: rhEPO 500
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 500 IU/mL plus methylprednisolone (M + E group)
Study: 38884324
Drug: Tenecteplase (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.25 mg/kg, max 25 mg)
Study: 38884332
Drug: Alteplase (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (0.9 mg/kg, max 90 mg)
Study: 33806189
Drug: Fixed prostheses
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed prostheses supported by zygomatic implants (2–4 zygomatic and 2–4 conventional implants)
Study: 33806189
Drug: All-on-four concept
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-on-four concept (fixed prostheses on four implants)
Study: 36017797
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (3.5 mg/kg)
Study: 36107485
Drug: Pre-chemotherapy NLR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy NLR
Study: 36107485
Drug: NLR score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLR score = pre-chemotherapy NLR + ΔNLR
Study: 36107485
Drug: NLR-attenuating anti-Ly6G
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NLR-attenuating anti-Ly6G treatment with gemcitabine/paclitaxel
Study: 33155041
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 30 mL 0.25% bupivacaine
Study: 33155041
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block with 30 mL saline
Study: 32884045
Drug: Spinal Manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Manipulative Therapy (SMT) at the lumbar segment measured as the stiffest
Study: 32884045
Drug: Spinal Manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Manipulative Therapy (SMT) at the lumbar segment measured as having the lowest pain threshold
Study: 34463164
Drug: ospemifene 60
Normalized name: ospemifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ospemifene 60 mg/day for 3 months
Study: 34463164
Drug: ospemifene 60
Normalized name: ospemifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ospemifene 60 mg/day for 6 months
Study: 33212239
Drug: Patient self-monitoring
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-monitoring via electronic medication monitoring and smartphone application plus remote clinician feedback
Study: 34166539
Drug: Fully guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully guided (FG) implant surgery
Study: 34166539
Drug: Conventionally guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally guided (CG) implant surgery
Study: 34090604
Drug: β‐lactam treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐lactam treatment for 3 days
Study: 34562081
Drug: Peanuts (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanuts (28 g/d)
Study: 33620405
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (1.5 g), thiamine (100 mg), and hydrocortisone (50 mg) every 6 hours (n=252)
Study: 36137125
Drug: Chemotherapeutic agents
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agents (specific agents not detailed)
Study: 35010984
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of bergamot phytosome® and 100 mg of artichoke leaf standardized dry extract
Study: 32964693
Drug: Nurse-led cognitive
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive behavioral group therapy for recovery of self-esteem (CBGTRS)
Study: 34784804
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided corticosteroid injection
Study: 32471729
Drug: Abicipar 2
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar 2 mg every 8 weeks after 3 initial doses at baseline and weeks 4 and 8 (Q8)
Study: 32471729
Drug: Abicipar 2
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar 2 mg every 12 weeks after 3 initial doses at baseline and weeks 4 and 12 (Q12)
Study: 32471729
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg every 4 weeks (Q4)
Study: 35156069
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg biannually for a total of four treatments
Study: 34462286
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg once daily for 40 weeks
Study: 34310072
Drug: CAET combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAET combined with traditional speech and language therapy (SLT)
Study: 32437921
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy planning according to INSEMA protocol
Study: 32437921
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose in axillary level I
Study: 32437921
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose in axillary levels II and III
Study: 32437921
Drug: Association between
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association between incidental radiation dose and obesity
Study: 86266805
Drug: R3: rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: R3: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months
Study: 86266805
Drug: R5: rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: R5: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months followed by streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months
Study: 32182879
Drug: BoNT‐A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injections into each masseter muscle
Study: 32182879
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections into each masseter muscle (placebo)
Study: 34973039
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus enhanced medication management (SERT+EMM)
Study: 32278278
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure plus Sertraline (PE+SERT)
Study: 32278278
Drug: Combat exposed
Normalized name: Provita Combat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combat exposed controls (CC)
Study: 36017028
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy combined with VEGF therapy (3 therapies for 1 month/time)
Study: 36017028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 therapies for 1.5 months/time)
Study: 33450291
Drug: Drug negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug negative urine
Study: 32593046
Drug: 5-plant extract
Normalized name: century plant whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-plant extract BNO 1012 in addition to standard symptomatic therapy
Study: 35318844
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy only
Study: 32768592
Drug: Basiliximab induction
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab induction with low dose steroids and MMF, delayed introduction of CNI (n=42)
Study: 32768592
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple immunosuppression (steroid, tacrolimus, and mycophenolate mofetil) (n=47)
Study: 35499569
Drug: TRX518 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX518 monotherapy
Study: 35499569
Drug: TRX518 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX518 in combination with gemcitabine (Part C)
Study: 35499569
Drug: TRX518 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX518 in combination with pembrolizumab (Part D)
Study: 35499569
Drug: TRX518 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX518 in combination with nivolumab (Part E)
Study: 35499569
Drug: TRX518 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRX518 monotherapy + anti-PD1 combination
Study: 33822027
Drug: Heavy force
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy force (H, 500 g)
Study: 33822027
Drug: Light force
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light force (L, 300 g)
Study: 33913086
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg once daily
Study: 35226949
Drug: ReWin(d) supplement
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReWin(d) supplement